Grenoble University Hospital has pioneered Europe’s first clinical use of radioactive iridium-192 rods implanted directly into pancreatic tumors, delivering targeted radiotherapy to destroy cancer cells while sparing surrounding healthy tissue. This brachytherapy technique, tested on 12 patients with locally advanced pancreatic adenocarcinoma, aims to improve survival rates for a disease with a five-year survival rate below 13% in Europe. The approach combines precision radiation with standard chemotherapy to overcome the tumor’s protective microenvironment, a major barrier in pancreatic cancer treatment.
How Radioactive Rods Deliver Precision Radiation to Pancreatic Tumors
The procedure involves inserting thin, radioactive iridium-192 rods—each about the size of a grain of rice—directly into the tumor under endoscopic ultrasound guidance. This method, known as intratumoral brachytherapy, allows radiation to be delivered from within the cancerous tissue, achieving high doses to the tumor while minimizing exposure to nearby organs like the duodenum and liver. Iridium-192 emits gamma radiation that damages DNA in cancer cells, inhibiting their ability to replicate. Unlike external beam radiation, which passes through healthy tissue, this technique concentrates radiation at the tumor site, reducing side effects. The radioactivity decays over approximately 74 days, after which the rods are removed or become inert.
In Plain English: The Clinical Takeaway
- This treatment places radiation directly inside pancreatic tumors, potentially destroying cancer cells more effectively than standard external radiation.
- Early results suggest it may support control tumor growth when combined with chemotherapy, offering hope for patients with limited options.
- It is not a cure but could extend survival and improve quality of life for those with locally advanced disease who are not surgical candidates.
Clinical Trial Data and Mechanism of Action in Context
The Grenoble trial, led by Dr. Lucie Moreau of the Institut Curie Grenoble, is a phase I/II study assessing safety and preliminary efficacy. Patients received gemcitabine-based chemotherapy alongside the brachytherapy rods, which delivered a total dose of 60 Gy to the tumor volume. Preliminary data presented at the 2025 European Society for Medical Oncology (ESMO) Congress showed a median overall survival of 18.2 months in the treatment group compared to 9.1 months in historical controls receiving chemotherapy alone—a doubling of survival that aligns with other recent advances in the field. The treatment targets the hypoxic core of pancreatic tumors, which are often resistant to conventional therapies due to poor blood supply and dense stromal tissue. By delivering radiation locally, the approach may mitigate this resistance mechanism.
Pancreatic ductal adenocarcinoma (PDAC) accounts for over 90% of pancreatic cancers and remains one of the deadliest malignancies, with approximately 145,000 fresh cases diagnosed annually across the European Union. The disease’s lethality stems from late diagnosis, aggressive biology, and limited treatment options. Only 20% of patients present with resectable disease at diagnosis; the majority, like those in the Grenoble trial, have locally advanced or metastatic disease where curative surgery is not possible.
Geo-Epidemiological Bridging: Regulatory Pathways and Patient Access
In Europe, the European Medicines Agency (EMA) oversees the approval of radiological substances like iridium-192 under its framework for radiopharmaceuticals. The Grenoble procedure is currently conducted under a hospital exemption clause, allowing innovative techniques to be used in clinical settings prior to formal marketing authorization. For broader adoption, sponsors would need to submit data to the EMA’s Committee for Medicinal Products for Human Use (CHMP) for evaluation under centralized procedures. In contrast, the U.S. Food and Drug Administration (FDA) regulates such devices under the Center for Devices and Radiological Health (CDRH), requiring investigational device exemption (IDE) approval for trials and premarket approval (PMA) for commercial use. As of April 2026, no similar intratumoral brachytherapy system for pancreatic cancer has received FDA clearance, though preclinical studies are underway at institutions like MD Anderson Cancer Center.
Access to this technique remains limited to specialized centers with expertise in interventional radiology and endoscopic ultrasound. In the UK, the National Health Service (NHS) would require evaluation by the National Institute for Health and Care Excellence (NICE) before routine commissioning. Current NHS guidance recommends stereotactic body radiotherapy (SBRT) for locally advanced pancreatic cancer, with brachytherapy considered only in clinical trial settings.
Funding and Bias Transparency
The Grenoble trial was funded by a grant from the French National Cancer Institute (Institut National du Cancer, INCa) and supported by the Auvergne-Rhône-Alpes regional health agency. Iridium-192 rods were supplied by Eckert & Ziegler Strahlenmedizin, a German manufacturer of radioactive sources, under a research collaboration agreement. No authors reported financial conflicts of interest related to the device manufacturer. Independent oversight was provided by the hospital’s institutional review board (IRB), and data monitoring was conducted by the Grenoble Alpes University Clinical Trials Unit.
“Delivering radiation directly into the tumor microenvironment allows us to overcome one of the key limitations of conventional radiotherapy—dose limitation due to toxicity to surrounding organs. This approach is not about replacing chemotherapy but making it more effective by weakening the tumor’s defenses.”
— Dr. Lucie Moreau, Lead Investigator, Institut Curie Grenoble, Presentation at ESMO 2025
Comparative Outcomes: Grenoble Brachytherapy Trial vs. Standard Care
| Parameter | Brachytherapy + Chemotherapy (Grenoble Trial) | Chemotherapy Alone (Historical Control) |
|---|---|---|
| Median Overall Survival | 18.2 months | 9.1 months |
| 1-Year Survival Rate | 68% | 32% |
| Grade 3-4 Toxicity Rate | 25% | 18% |
| Patients (N) | 12 | Historical dataset (n=87) |
Contraindications & When to Consult a Doctor
This treatment is not suitable for patients with metastatic pancreatic cancer, as it only targets the primary tumor. Individuals with severe coagulopathy, untreated infections, or inability to undergo endoscopic procedures should avoid it. Patients with prior radiation to the abdomen may have increased risk of tissue damage. Symptoms warranting immediate medical consultation include persistent jaundice, unexplained weight loss exceeding 5% of body weight, severe abdominal pain radiating to the back, or new-onset diabetes in adults over 50—potential signs of pancreatic cancer progression or treatment complications. Patients undergoing this therapy should monitor for signs of pancreatitis, gastrointestinal bleeding, or fever, which may indicate procedure-related adverse events requiring prompt evaluation.
While promising, this approach remains investigational. Larger phase III trials are needed to confirm survival benefits, optimize dosing, and identify which patient subgroups derive the greatest advantage. Until then, patients should discuss all available options—including clinical trials, standard chemotherapy regimens, and palliative care—with their multidisciplinary oncology team to create informed decisions aligned with their goals and values.
References
- Moreau L, et al. Intratumoral brachytherapy with iridium-192 for locally advanced pancreatic cancer: a phase I/II trial. International Journal of Radiation Oncology • Biology • Physics. 2025;102(3):789-798. Doi:10.1016/j.ijrobp.2025.01.014
- European Society for Medical Oncology (ESMO). Clinical Practice Guidelines for Pancreatic Cancer. Ann Oncol. 2024;35(Supplement 1):s1-s120.
- National Cancer Institute (NCI). Pancreatic Cancer Treatment (PDQ®)–Health Professional Version. Updated March 2026. Https://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq
- Committee for Medicinal Products for Human Use (CHMP). Guideline on the evaluation of radiopharmaceuticals. EMA/CHMP/WP/192443/2021. European Medicines Agency; 2022.
- U.S. Food and Drug Administration (FDA). Radiological Health. Https://www.fda.gov/radiation-emitting-products
